臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"wu chou"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 21-45 / 62 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
國立成功大學	2022-05-20	Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naive Metastatic Lung Adenocarcinoma	Yang;Szu-Chun;Lin;Chien-Chung;Chen;Yi-Lin;Su;Wu-Chou
國立成功大學	2022-02-28	The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy	Su;Po-Lan;Chen;Jung-Yueh;Chu;Chang-Yao;Chen;Yi-Lin;Chen;Wan-Li;Lin;Kuan-Yu;Ho;Chung-Liang;Tsai;Jeng-Shiuan;Yang;Szu-Chun;Chen;Chian-Wei;Wu;Yi-Lin;Tseng;Yau-Lin;Chang;Chao-Chun;Yen;Yi-Ting;Lin;Chia-Ying;Lin;Chien-Chung;Su;Wu-Chou
國立成功大學	2022-01-7	FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer	Chung;Wei-Pang;Huang;Wei-Lun;Liao;Wei-An;Hung;Chun-Hua;Chiang;Chi-Wu;Cheung;Antonio, Chun Hei;Su;Wu-Chou
國立成功大學	2022-01	Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors	Wang;Sheng-Yuan;Lai;Ching-Han;Chen;Chian-Wei;Yang;Szu-Chun;Chang;Chao-Chun;Lin;Chia-Ying;Yen;Yi-Ting;Tseng;Yau-Lin;Su;Po-Lan;Lin;Chien-Chung;Su;Wu-Chou
國立成功大學	2022	PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations	Chung;Wei-Pang;Huang;Wei-Lun;Lee;Chun-Hui;Hsu;Hui-Ping;Huang;Wan-Ling;Liu;You-Yu;Su;Wu-Chou
國立成功大學	2022	Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy	Yang;Pei-Shan;Yu;Min-Hua;Hou;Ya-Chin;Chang;Chih-Peng;Lin;Shao-Chieh;Kuo;I-Ying;Su;Pei-Chia;Cheng;Hung-Chi;Su;Wu-Chou;Shan;Yan-Shen;Wang;Yi-Ching
國立成功大學	2021-12	Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer	Huang;Yi-Hsuan;Lin;Peng-Chan;Su;Wu-Chou;Chan;Ren-Hao;Chen;Po-Chuan;Lin;Bo-Wen;Shen;Meng-Ru;Chen;Shang-Hung;Yeh;Yu-Min
國立成功大學	2021-11	CD40 Pathway and IL-2 Expression Mediate the Differential Outcome of Colorectal Cancer Patients with Different CSF1R c.1085 Genotypes	Yeh;Yu-Min;Lin;Peng-Chan;Su;Wu-Chou;Shen;Meng-Ru
國立成功大學	2021-09-24	Development of a novel ALK rearrangement screening test for non-small cell lung cancers	Chen;Yi-Lin;Chen;Wan-Li;Cheng;Yi-Chia;Lin;Ming-Ching;Yang;Shu-Ching;Tsai;Hung-Wen;Lin;Chien-Chung;Su;Wu-Chou;Chow;Nan-Haw;Ho;Chung-Liang
國立成功大學	2021-09	EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis	Tsai;Jeng-Shiuan;Su;Po-Lan;Yang;Szu-Chun;Chang;Chao-Chun;Lin;Chia-Ying;Yen;Yi-Ting;Tseng;Yau-Lin;Lai;Wu-Wei;Lin;Chien-Chung;Su;Wu-Chou
國立成功大學	2021-05-14	Biocompatible hole scavenger-assisted graphene oxide dots for photodynamic cancer therapy	Shih;Chun-Yan;Huang;Wei-Lun;Chiang;I-Ting;Su;Wu-Chou;Teng;Hsisheng
國立成功大學	2021-04	Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models	Chung;Wei-Pang;Huang;Wei-Lun;Liao;Wei-An;Huang;Wan-Ling;Liu;You-Yu;Su;Wu-Chou
國立成功大學	2021-03-1	Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors	Tsai;Hui-Jen;Shiah;Her-Shyong;Chang;Jang-Yang;Su;Wu-Chou;Chiang;Nai-Jung;Chen;Li-Tzong
國立成功大學	2021-03	Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC	Lin;Chien-Chung;Wu;Chin-You;Tseng;Joseph, Ta-Chien;Hung;Chun-Hua;Wu;Shang-Yin;Huang;Yu-Ting;Chang;Wei-Yuan;Su;Po-Lan;Su;Wu-Chou
國立成功大學	2021-02	First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer	Su;Po-Lan;Chen;Chian-Wei;Wu;Yi-Lin;Lin;Chien-Chung;Su;Wu-Chou
國立成功大學	2021-02	Nanomedicine-Based Strategies Assisting Photodynamic Therapy for Hypoxic Tumors: State-of-the-Art Approaches and Emerging Trends	Shih;Chun-Yan;Wang;Pei-Ting;Su;Wu-Chou;Teng;Hsisheng;Huang;Wei-Lun
國立成功大學	2021	Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment	Kuo;I-Ying;Yang;You-En;Yang;Pei-Shan;Tsai;Yu-Jou;Tzeng;Hong-Tai;Cheng;Hung-Chi;Kuo;Wan-Ting;Su;Wu-Chou;Chang;Chih-Peng;Wang;Yi-Ching
國立成功大學	2020-10	Clinical Frailty Scale in Predicting Postoperative Outcomes in Older Patients Undergoing Curative Surgery for Urologic Malignancies: A Prospective Observational Cohort Study	Sun;Chien-Yao;Huang;Chien-Cheng;Tsai;Yuh-Shyan;Chang;Yu-Tzu;Ou;Chien-Hui;Su;Wu-Chou;Fan;Sheng-Yu;Wang;Shan-Tair;Yang;Deng-Chi;Huang;Chi-Chang;Chang;Chia-Ming
國立成功大學	2020-08	Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients	Li;Feng;Wei;Fang;Huang;Wei-Lun;Lin;Chien-Chung;Li;Liang;Shen;Macy, Macy M.;Yan;Qingxiang;Liao;Wei;Chia;David;Tu;Michael;Tang;Jason, H.;Feng;Ziding;Kim;Yong;Su;Wu-Chou;Wong;David, T. W.
國立成功大學	2020-07-16	Immune Checkpoint Inhibitor-Induced Myasthenia Gravis	Huang;Yi-Te;Chen;Ya-Ping;Lin;Wen-Chih;Su;Wu-Chou;Sun;Yuan-Ting
國立成功大學	2020-07	Assessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoring-Mass Spectrometry	Wu;Hsin-Yi;Pan;Yu-Yi;Kopylov;Arthur, T.;Zgoda;Victor;Ma;Mi-Chia;Wang;Ching-Hsun;Su;Wu-Chou;Lai;Wu-Wei;Cheng;Pin-Nan;Liao;Pao-Chi
國立成功大學	2020-05-14	Silver-coated zero-valent iron nanoparticles enhance cancer therapy in mice through lysosome-dependent dual programed cell death pathways: triggering simultaneous apoptosis and autophagy only in cancerous cells	Yang;Li-Xing;Wu;Ya-Na;Wang;Pei-Wen;Huang;Kuang-Jing;Su;Wu-Chou;Shieh;Dar-Bin
國立成功大學	2020-04-8	Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan	Yang;Szu-Chun;Lai;Wu-Wei;Hsu;Jason, C.;Su;Wu-Chou;Wang;Jung-Der
國立成功大學	2019-11	Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up	Yang;Szu-Chun;Kuo;Chin-Wei;Lai;Wu-Wei;Lin;Chien-Chung;Su;Wu-Chou;Chang;Sheng-Mao;Wang;Jung-Der
國立成功大學	2019-10	Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment	Su;Po-Lan;Yang;Szu-Chun;Chen;Yi-Lin;Wu;Yi-Lin;Lin;Chia-Ying;Chang;Wei-Yuan;Tseng;Yau-Lin;Lai;Wu-Wei;Ho;Chung-Liang;Lin;Chien-Chung;Su;Wu-Chou

显示项目 21-45 / 62 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 51773430 在线人数 : 1024 教育部委托研究计画计画执行:国立台湾大学图书馆